scholarly journals Effectiveness of proprotein convertase subtilisin/kexin‐9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic

2021 ◽  
Author(s):  
Anindita Chakraborty ◽  
Jing Pang ◽  
Dick C. Chan ◽  
Wendy Barnett ◽  
Ann Marie Woodward ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Plasma Lipoprotein ◽  
Proprotein Convertase ◽  
Antibody Treatment ◽  
Lipoprotein A ◽  
Monoclonal Antibody Treatment

scholarly journals AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy

Circulation ◽  
2013 ◽  
Vol 128 (9) ◽  
pp. 962-969 ◽  
Author(s):  
Nihar R. Desai ◽  
Payal Kohli ◽  
Robert P. Giugliano ◽  
Michelle L. O’Donoghue ◽  
Ransi Somaratne ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Statin Therapy ◽  
Proprotein Convertase ◽  
Lipoprotein A

scholarly journals Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment

Healthcare ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 990
Author(s):  
Herman Morchel ◽  
David Clark ◽  
Leighanne Buenvenida ◽  
Chinwe Ogedegbe
Keyword(s):  
Emergency Department ◽  
Monoclonal Antibody ◽  
Patient Care ◽  
Emergency Care ◽  
Environmental Changes ◽  
Physical Space ◽  
Antibody Treatment ◽  
Monoclonal Antibody Treatment ◽  
Mobile Satellite ◽  
Novel Coronavirus

The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance entrance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing.

Sign in / Sign up

Export Citation Format

Share Document